Experiments in progress

Playing a significant role in the pursuit of wellbeing in the meaning of wider vision of health.

Experiments in progress

We are ready to start testing some interesting applications:


Respiratory diseases
- Covid-19
- Pneumonia syndrome


Liver Diseases
- NAFLD:Non-alcoholic fatty liver disease
- NASH: Non-alcoholic steatohepatitis


Neuro-degeneration
- Alzhaimers
- Dementia

Respiratory diseases

THE PROBLEM

Acute Respiratory Distress Syndrome (ARDS) is a type of respiratory failure characterised by a rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath, rapid breathing and bluish discoloration of the skin. For Acute Respiratory Distress Syndrome (ARDS) is a type of respiratory failure characterised by a rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath, rapid breathing and bluish discoloration of the skin. For those who survive, a decrease in quality of life is common.

The altered protein profile (cytokine) of COVID-19 patients appears to be one of the causes of death, including a high concentration of ferritin which appears to be a predictor of COVID-19 mortality..

Experiments in progress | Innbiotec Pharma

THE CURRENT MARKET AND TREATMENTS

PREVALENCE

Experiments in progress | Innbiotec Pharma

The prevalence of ARDS, in cases related to COVID, can be up to 0.5 %.

CURRENT THERAPY

No current drug therapy.

Pharmacological support therapies::
- Anti-inflammatories
- Cortisone
- Anticoagulants
- Generic antivirals

Supporto non farmacologico:
- Ventilazione meccanica
- Ossigenoterapia

OUR SOLUTIONS

- Clinical studies with GSH inhaled in ARDS patients have shown benefits.
- There is documented strong oxidative stress in lung tissue during ARDS.
- The reduction of GSH in hive tissue and surfactant is documented.
-The lung surfactant in ARDS patients leads to increased surface tension;
- This leads to collapse of the pulmonary alveolus;
- In turn, pulmonary exchanges are reduced.
-By reducing the surface tension of the surfactant, our molecule can help alleviate the problem considerably and assist in the healing process.

Liver diseases

THE PROBLEM

- The liver has many important functions, including digestion of food, processing and distribution of nutrients.
- There are many types of liver diseases and conditions.
- Some, such as hepatitis, are caused by viruses.
- Others may be the result of drugs or the consumption of too much alcohol.
- Non-alcoholic fatty liver disease is one of the most common liver diseases in the United States.

Experiments in progress | Innbiotec Pharma

Very common diseases: we expect to be able to reach 11M people.

Experiments in progress | Innbiotec Pharma

Global prevalence

NAFLD: about 25% of the population
NASH: about 4% of the adult population

USA+UE

NAFLD: about 24% of the adult population.
NASH: about 4% of the adult population

Population reached

NAFLD: about 5% of NAFLD patients
NASH: about 15% of NASH patients

CURRENT TREATMENTSI
No pharmacological treatment has yet been approved

- Weight loss through a combination of healthy diet and exercise.
- Ideally: 10% weight loss.
-Improvement: 3% to 5% weight loss.
- Weight loss surgery is also an option for those who need to lose a lot of weight.
- IIn case of cirrhosis due to NASH, liver transplantation can be an option

Potential treatments

- No drug treatment has been approved by the Food and Drug Administration for non-alcoholic fatty liver diseases or NASH.
- Some drugs are under study.

Alternative medicine

- Vitamin E: Vitamin E may help protect the liver by reducing or neutralising the damage caused by inflammation.
- Coffee: In studies of people with non-alcoholic fatty liver disease, those who reported drinking two or more cups of coffee a day had less liver damage than those who drank little or no coffee. It is not yet clear how coffee can affect liver damage, but the results suggest that it may contain certain compounds that may play a role in the fight against inflammation.

The literature and external animal models have given positive results

-Recent attempts to establish effective NAFLD and NASH therapies have identified potential micronutrients with antioxidant power that can reduce fat accumulation and possibly improve disease.

- The components of our molecule have proven to be protective against animal models of steatohepatitis, preventing many aspects of NASH progression by improving liver histology and - The components of our molecule have proven to be protective against animal models of steatohepatitis, preventing many aspects of NASH progression by improving liver histology and decreasing oxidative stress, resulting in increased anti-inflammatory protections.

- Finally, a recent study has been carried out in rats with the induced NAFLD diet treated with components of our molecule. The results indicate a significant improvement in liver and related NAFLD/NASH indices.

The latter data suggests the opportunity to search for combinations between anti-NASH compounds in order to find formulations with synergistic effects.

Neuro-degeneration

THE PROBLEM

Experiments in progress | Innbiotec Pharma

THE MARKET AND CURRENT TREATMENTS

Prevalence of Alzheimer's.

Experiments in progress | Innbiotec Pharma

The prevalence of Alzheimer's in the population over the age of 80 is about 4 times the normal population.

CURRENT TREATMENTS

- No current drug therapy
- Many studies suggest that preventive therapy based on eating habits and life activities can help reduce incidence

OUR SOLUTIONS

-Oleuropein and bioavailable GSH have demonstrated on animal models the ability to reduce aggregation and toxicity of amyloid beta peptide.
- This suggests a potential protective role against the neurodegeneration associated with the pathological brain aging of Alzheimer's disease.
-Initiated a 12-month observational study of 40 people at the University of Rome hospital.
- Positive preliminary results suggest:
- Strong deceleration in cognitive performance reduction (MMS test).
- Improved tumor markers and reduction in neuro capacity loss (through image analysis such as CT and PET).

contact an expert

Do you need help?

We are here for you, ready to answer your questions.